Verrica Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	69.55	34.27	15.75	10.69	9.24	10.77	8.66	0.53
Short-Term Investments	0	0	54.6	54.78	52.78	79.54	0	0
Cash & Cash Equivalents	69.55	34.27	70.35	65.47	62.02	90.31	8.66	0.53
Cash Growth	102.92%	-51.28%	7.46%	5.57%	-31.33%	942.46%	1543.83%	-
Receivables	4.42	0.49	0	0	0	0	0	0
Inventory	1.02	0	0	0	0	0	0	0
Other Current Assets	2.55	4.36	3.97	2.18	2.97	0.84	0.42	0.02
Total Current Assets	77.53	39.12	74.33	67.65	64.98	91.15	9.08	0.54
Property, Plant & Equipment	3.62	5.33	5.5	4.94	2.2	0.26	0	0
Other Long-Term Assets	0.45	0.28	0.3	1.57	1.24	0.5	0	0
Total Long-Term Assets	4.07	5.61	5.8	6.5	3.44	0.75	0	0
Total Assets	81.6	44.72	80.13	74.15	68.42	91.91	9.08	0.54
Accounts Payable	2.46	0.51	0.85	0.35	1.19	0.96	0.17	0.1
Deferred Revenue	0	0	0	0.5	0	0	0	0
Current Debt	0.7	0.3	41.94	35.51	0.13	0	0	0
Other Current Liabilities	13.86	2.66	3.27	3.11	2.04	1.52	0.45	0.32
Total Current Liabilities	17.02	3.46	46.06	39.48	3.35	2.48	0.62	0.42
Long-Term Debt	44.81	1.23	1.47	1.69	0.06	0	0	0
Total Long-Term Liabilities	44.81	1.23	1.47	1.69	0.06	0	0	0
Total Liabilities	61.83	4.69	47.52	41.17	3.41	2.48	0.62	0.42
Total Debt	45.51	1.53	43.41	37.21	0.19	0	0	0
Debt Growth	2882.31%	-96.48%	16.67%	19690.43%	-	-	-	-
Retained Earnings	-230.45	-163.45	-138.97	-103.89	-61.19	-33.08	-12.44	-2.68
Comprehensive Income	0	0	-0.03	0	0.02	-0.02	0	0
Shareholders' Equity	19.76	40.03	32.61	32.99	65.02	89.43	-7.04	-2.66
Net Cash / Debt	24.04	32.75	26.95	28.26	61.83	90.31	8.66	0.53
Net Cash / Debt Growth	-26.60%	21.53%	-4.67%	-54.29%	-31.54%	942.46%	1543.83%	-
Net Cash Per Share	0.53	0.96	1.00	1.13	2.48	6.16	3.04	0.08
Working Capital	60.51	35.66	28.27	28.18	61.63	88.68	8.47	0.13
Book Value Per Share	0.44	1.17	1.21	1.32	2.61	6.10	-2.47	-0.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).